drugset / Trial / NCT02085590

Effects of BCG on Immune Response

NCT02085590

Phase 2/3 Completed 20 enrolled Radboud University Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In the present study, we want to investigate whether BCG-vaccination enhances the innate immune response in humans in vivo during (single) human endotoxemia. In a future experiment we will investigate whether BCG-vaccination can reverse the tolerant state observed upon a second LPS administration. Our goal is to ultimately translate our results into clinic applications to reverse for example sepsis-induced immunoparalysis.

Timeline

Start
2014-03
Primary completion
2014-10
Completion
2014-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator BCG vaccine Vaccine 0.1 ml Intravitreal
Comparator BCG vaccine Vaccine 0.75 mg/ml Intravitreal